Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With High Risk, Early Stage Globo H-Positive Triple Negative Breast Cancer

NCT03562637 is registered in ClinicalTrials.gov with OBI Pharma, Inc as lead sponsor.

NCT NCT03562637
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03562637 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With High Risk, Early Stage Globo H-Positive Triple Negative Breast Cancer
Lead sponsor
OBI Pharma, Inc
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 5, 2018
Completion date
December 30, 2027
Enrollment
575 (actual)
Sites
128

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer